Coronary side effects dash Amgen, UCB hopes for osteoporosis drug

New York

AMGEN Inc and UCB SA no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.

The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the Food and Drug Administration.